go-v.orgdoi

Fixed combination therapies based on direct renin inhibition: a commentary to the ACCELERATE trial

Giuliano Tocci, Diana Chin, Massimo Volpe · Clinical Investigation · 2011

  • DOI 10.4155/cli.11.37
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2011

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2011

Abstract

Despite the well-established concept that the treatment of high blood pressure (BP) represents a key strategy in reducing the burden of cardiovascular (CV) and renal diseases, arterial hypertension remains poorly controlled worldwide. To improve BP control in the hypertensive population, a more extensive use of combination therapies rather than monotherapies should be adopted, even as a first-line approach, in patients with grade 2–3 hypertension, in high-risk individuals or in those who need more ambitious BP goals (e.g., diabetics).

Today, this represents an emerging clinical strategy for the daily clinical practice of hypertension, since recent randomized clinical trials have demonstrated the efficacy, safety and tolerability of such therapeutic approach. Among the potentially effective antihypertensive-combination strategies currently available for the clinical management of hypertension, those based on the combination of drugs inhibiting the renin–angiotensin system (RAS) and calcium-channel blockers (CCBs) appear to ensure effective and extended control of BP levels, as well as CV and renal protection.

The recent availability of a novel class of antihypertensive drugs, the direct renin inhibitors (DRI), has prompted studies to further investigate the use of combination strategies to achieve a rapid, persistent and effective BP control. In the present article, we discuss the interesting findings of a recent randomized clin ical trial, the Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension (ACCELERATE) trial, which investigated the BP lowering effect and the tolerability of the combination of two long-acting compounds, the calcium-channel blocker amlodipine besylate and the DRI aliskiren.

Fixed combination therapy for the clinical management of hypertension Blood pressure elevation is paralleled by a progressive increase in the risk of developing major CV events, including myocardial infarction and stroke, independently of age and gender [1]. The reduction and, most importantly, normalization of BP levels in hypertensive patients is, in turn, associated with significant CV benefits [2]. Achievement of recommended BP targets, however, remains poorly accomplished in both western and developing countries, and recent international surveys demonstrated that almost three quarters of treated hypertensive patients are not normalized under pharmacological treatment [3–5].

Among the potential factors that may contribute to this disappointing observation, frequent presence of comorbidities, doctors’ clinical inertia and the widespread use of monotherapy rather than combination therapy, may all play an important 1

Open the resolved locator · 10.4155/cli.11.37

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 03:41 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.11.37
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.